Home/Pipeline/TSY-310

TSY-310

Solid tumors (bispecific ADC)

DevelopmentActive

Key Facts

Indication
Solid tumors (bispecific ADC)
Phase
Development
Status
Active
Company

About Formosa Pharmaceuticals

A clinical-stage biotech company developing ophthalmology and oncology therapies using its proprietary APNT® nanoparticle platform and ADC technology.

View full company profile